SAN DIEGO, April 19, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (“IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. ...

文章核心观点 罗森律师事务所代表购买Zenas BioPharma证券的投资者提起集体诉讼，指控该公司招股说明书存在虚假或误导性陈述，投资者可能获得赔偿 [1][2][5] 案件详情 - 招股说明书包含虚假或误导性陈述，未披露公司夸大用现有现金和IPO预期净收益维持运营的时间 [5] - 被告公开声明在相关时间存在重大虚假和误导性，且准备疏忽，导致投资者受损 [5] 投资者权益 - 购买Zenas BioPharma证券的投资者可通过风险代理安排获得赔偿，无需支付额外费用 [2] - 投资者能否分享未来潜在赔偿与是否担任首席原告无关 [7] 参与诉讼方式 - 加入集体诉讼可访问https://rosenlegal.com/submit - form/?case_id = 37109 ，或致电866 - 767 - 3653 ，或发邮件至[email protected] [3][6] - 若想担任首席原告，需在2025年6月16日前向法院提出申请 [1][3] 律所优势 - 罗森律师事务所代表全球投资者，专注证券集体诉讼和股东派生诉讼 [4] - 曾达成针对中国公司有史以来最大的证券集体诉讼和解 [4] - 2017年证券集体诉讼和解数量排名第一，2013年以来每年排名前四，为投资者追回数亿美元 [4] - 2019年为投资者追回超4.38亿美元，2020年创始合伙人获行业认可 [4]

NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”). If you wish to serve as lead plaintiff, you must move th ...

SAN DIEGO, April 18, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a "clinical stage global biopharmaceutical company committed to being a leader in the development and co ...

SAN DIEGO, April 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit.  Captioned Bu ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Zenas BioPharma, Inc. (“Zenas BioPharma” or the “Company”) (NASDAQ: ZBIO) securities in connection with the initial public offering (the “IPO”) held on or around September 13, 2024 (the “Class Period”) and/or which said securities are ...

WASHINGTON, April 17, 2025 (GLOBE NEWSWIRE) -- Investors who lost money on securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) purchased pursuant and/or traceable to the Zenas BioPharma’s September 2024 initial public offering (the “IPO”) are encouraged to contact Cohen Milstein Sellers & Toll PLLC to learn about a recently filed securities class action lawsuit. [Click here for information about joining the class action] CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developin ...

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducemen ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquir ...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”). If you wish to serve as lead plaintiff, you must move th ...